Its mechanism reduces off-target toxicity and provides a high level of drug exposure at the MTD for sustained VEGFR inhibition, which can be used alone or with other therapeutic agents for a comprehensive anti-tumor effect (Figure 1). This evidence concerns the gene KDR and neoplasm.